Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN)

Cybin Inc (CYBN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,235
  • Shares Outstanding, K 410,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,930 K
  • 60-Month Beta 0.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.69
Trade CYBN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings $-0.07 on 02/14/24
  • Latest Earnings Date 02/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate -0.02
  • Low Estimate -0.04
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3513 +6.86%
on 04/16/24
0.4699 -20.11%
on 04/03/24
-0.0846 (-18.39%)
since 03/15/24
3-Month
0.2831 +32.60%
on 02/07/24
0.5224 -28.14%
on 03/13/24
-0.0056 (-1.47%)
since 01/17/24
52-Week
0.2100 +78.76%
on 06/06/23
0.7380 -49.13%
on 10/31/23
-0.0136 (-3.50%)
since 04/17/23

Most Recent Stories

More News
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 0.5100 (-3.77%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3754 (-1.11%)
ATAI : 1.9800 (-7.91%)
MNMD : 9.53 (-3.54%)
SEEL : 0.3320 (-13.79%)
CMPS : 8.53 (-2.85%)
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...

CYBN : 0.3754 (-1.11%)
CYBN.NE : 0.5100 (-3.77%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...

NTRBW : 0.5000 (+38.89%)
CYBN : 0.3754 (-1.11%)
NTRB : 4.27 (+6.48%)
CMND : 1.1900 (-2.46%)
MNMD : 9.53 (-3.54%)
LLY : 750.77 (+0.54%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END

NTRB : 4.27 (+6.48%)
NTRBW : 0.5000 (+38.89%)
CMND : 1.1900 (-2.46%)
MNMD : 9.53 (-3.54%)
CYBN : 0.3754 (-1.11%)
LLY : 750.77 (+0.54%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.5100 (-3.77%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3754 (-1.11%)
CMPS : 8.53 (-2.85%)
SEEL : 0.3320 (-13.79%)
MNMD : 9.53 (-3.54%)
NUMIF : 0.0637 (+23.69%)
NUMI.TO : 0.0850 (+21.43%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...

NUMI.TO : 0.0850 (+21.43%)
CYBN : 0.3754 (-1.11%)
CMPS : 8.53 (-2.85%)
MNMD : 9.53 (-3.54%)
SEEL : 0.3320 (-13.79%)
NUMIF : 0.0637 (+23.69%)
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder

/CNW/ - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ("Cybin"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by...

CYBN : 0.3754 (-1.11%)
Cybin to Participate at the 26th Annual Milken Institute Global Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.5100 (-3.77%)
CYBN : 0.3754 (-1.11%)
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.5100 (-3.77%)
CYBN : 0.3754 (-1.11%)
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?

Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year.

CYBN : 0.3754 (-1.11%)
IPSEY : 28.6225 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 0.3945
2nd Resistance Point 0.3870
1st Resistance Point 0.3812
Last Price 0.3754
1st Support Level 0.3679
2nd Support Level 0.3604
3rd Support Level 0.3546

See More

52-Week High 0.7380
Fibonacci 61.8% 0.5363
Fibonacci 50% 0.4740
Fibonacci 38.2% 0.4117
Last Price 0.3754
52-Week Low 0.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar